| Dr Sean C Gilbey, MD | |
|
5920 W William Cannon Dr, Bldg 1 Ste 150, Austin, TX 78749-1902 | |
| (512) 441-9799 | |
| (512) 441-9814 |
| Full Name | Dr Sean C Gilbey |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 29 Years |
| Location | 5920 W William Cannon Dr, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184628828 | NPI | - | NPPES |
| 147946104 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | K6589 (Texas) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | K6589 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St David's South Austin Medical Center | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Pulmonary Consultants Pa | 5496853129 | 13 |
News Archive
Antibiotic resistance is a growing global health threat. So much so that a 2014 study commissioned by the Prime Minister of the United Kingdom predicted that, if the problem is left unchecked, in less than 35 years more people will die from antibiotic-resistant superbugs than from cancer.
AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as "AIDS cocktails."
"The FDA's review today of BiDil could make it the first drug approved specifically for African Americans and marks the end of 'one-size-fits-all' medicine," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group.
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
› Verified 5 days ago
| Entity Name | Cogent Healthcare Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20061121000364 |
News Archive
Antibiotic resistance is a growing global health threat. So much so that a 2014 study commissioned by the Prime Minister of the United Kingdom predicted that, if the problem is left unchecked, in less than 35 years more people will die from antibiotic-resistant superbugs than from cancer.
AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as "AIDS cocktails."
"The FDA's review today of BiDil could make it the first drug approved specifically for African Americans and marks the end of 'one-size-fits-all' medicine," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group.
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
› Verified 5 days ago
| Entity Name | Austin Pulmonary Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881741734 PECOS PAC ID: 5496853129 Enrollment ID: O20070604000703 |
News Archive
Antibiotic resistance is a growing global health threat. So much so that a 2014 study commissioned by the Prime Minister of the United Kingdom predicted that, if the problem is left unchecked, in less than 35 years more people will die from antibiotic-resistant superbugs than from cancer.
AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as "AIDS cocktails."
"The FDA's review today of BiDil could make it the first drug approved specifically for African Americans and marks the end of 'one-size-fits-all' medicine," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group.
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean C Gilbey, MD 5920 W William Cannon Dr, Bldg 1 Ste 150, Austin, TX 78749-1902 Ph: (512) 441-9799 | Dr Sean C Gilbey, MD 5920 W William Cannon Dr, Bldg 1 Ste 150, Austin, TX 78749-1902 Ph: (512) 441-9799 |
News Archive
Antibiotic resistance is a growing global health threat. So much so that a 2014 study commissioned by the Prime Minister of the United Kingdom predicted that, if the problem is left unchecked, in less than 35 years more people will die from antibiotic-resistant superbugs than from cancer.
AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as "AIDS cocktails."
"The FDA's review today of BiDil could make it the first drug approved specifically for African Americans and marks the end of 'one-size-fits-all' medicine," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group.
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
› Verified 5 days ago
Dr. Tatiana B. Jacobson, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd. Bldg C Ste. 102, Austin, TX 78746 Phone: 512-323-5465 Fax: 512-327-1390 | |
Preeti Venkatraman, M.B.B.S. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-7000 | |
Pritesh Harish Gandhi, M.D., M.P.H. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1101 Camino La Costa, Austin, TX 78752 Phone: 512-684-1832 | |
Dr. Joshua Lane Davis, D.O. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1004 W 32nd St Unit 300, Austin, TX 78705 Phone: 512-324-3440 | |
Dr. Analicia Alvarado, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-324-7000 | |
Dr. Grace Marie Grant-jennings, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Dr. Debra Ann Patt, MD, MPH Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6204 Balcones Dr, Austin, TX 78731 Phone: 512-427-9400 Fax: 512-342-2723 |